MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD, Nov. 09, 2020 (GLOBE NEWSWIRE) --
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in November and December:
- Credit Suisse 29th Annual Virtual Healthcare Conference. MacroGenics’ management will participate in one-on-one meetings and provide a corporate overview on November 10, 2020 at 2:45 PM ET.
- Stifel 2020 Virtual Healthcare Conference. MacroGenics’ management will participate in one-on-one meetings and participate in a fireside chat with the analyst on November 17, 2020 at 10:40 AM ET.
- SVB Leerink Oncology 1x1 Day. MacroGenics’ management will participate in one-on-one meetings on November 19, 2020.
- Evercore ISI 3rd Annual HealthCONx Virtual Conference. MacroGenics’ management will participate in one-on-one meetings and participate in a fireside chat with the analyst on December 2, 2020 at 3:55 PM ET.
Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at . The Company will maintain archived replays of these webcasts on its website for 30 days after each conference.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. For more information, please see the Company's website at . MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
###
Jim Karrels, Senior Vice President, CFO MacroGenics, Inc. 1-301-251-5172,
